3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Multiple Myeloma
20
Leukemia, Myeloid, Acute
8
Recurrence
7
Neoplasms, Plasma Cell
4
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma
3
Thymoma
2
Ovarian Neoplasms
2
Carcinoma
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Smoldering Multiple Myeloma
1
Small Cell Lung Carcinoma
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Richter's Transformation
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Oligodendroglioma
1
Neurofibrosarcoma
1
Neoplasms
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Melanoma
1
MDS
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
Paclitaxel
34
Carboplatin
27
pembrolizumab
20
Bevacizumab
16
Letrozole
13
Megestrol Acetate
10
Cisplatin
9
lenvatinib
8
olaparib
7
dostarlimab
7
Metformin
7
durvalumab
6
abemaciclib
6
Radiotherapy
6
Everolimus
6
niraparib
5
Specimen Handling
5
Nivolumab
5
Medroxyprogesterone Acetate
5
Magnetic Resonance Spectroscopy
5
Gemcitabine
5
Fluorouracil
5
Docetaxel
5
Biopsy
5
temsirolimus
4
rucaparib
4
Oxaliplatin
4
Fulvestrant
4
Doxorubicin
4
sapanisertib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Endometrial Neoplasms
×
selinexor
×
Clear all
NCT02025985
2023-01-26
SIGN
Karyopharm Therapeutics Inc
Phase 2
Completed
116 enrolled
21 charts